Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun;33(3):237-44.
doi: 10.1007/s10792-012-9678-2. Epub 2012 Nov 19.

Grading severity in retinitis pigmentosa using clinical assessment, visual acuity, perimetry and optical coherence tomography

Affiliations

Grading severity in retinitis pigmentosa using clinical assessment, visual acuity, perimetry and optical coherence tomography

Henry B Smith et al. Int Ophthalmol. 2013 Jun.

Abstract

To develop a grading system for retinitis pigmentosa (RP), providing clinicians with a simple, objective measure of disease severity. An observational case series of 14 patients with RP. Disease severity was assessed using four criteria; clinical appearance, visual acuity (best corrected LogMAR, BCVA), perimetry (mean deviation, MD) and Fourier-domain optical coherence tomography (outer retinal thickness, ORT at the fovea). Each criterion was scored on a severity scale from 0 (mild disease) to 4 (severe disease), giving an overall score out of 16. The mean BCVA was 0.37 LogMAR (range 0.02 to PL), mean MD was -25.35 dB (range -7.48 to -34.38 dB), mean retinal thickness at the fovea was 189.4 μm (range 96.5-264.5 μm) and mean ORT at the fovea was 140.6 μm (range 63.4-193.4 μm). The clinical appearance correlated well with each of the quantitative measures of disease severity; BCVA (0.62, p = 0.022), MD (-0.903, p < 0.0001) and ORT (-0.698, p = 0.005). Applying the grading system to our patients, the severity scores were evenly spread between grades 1 and 14. We present a simple, objective grading system for RP offering a potential tool for grading disease severity with applications such as assessing progression, comparing patient populations and measuring outcomes in clinical trials.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Invest Ophthalmol Vis Sci. 2011 Jul 29;52(8):5105-10 - PubMed
    1. Int Ophthalmol. 2001;23(4-6):321-5 - PubMed
    1. Am J Ophthalmol. 1999 Apr;127(4):436-42 - PubMed
    1. Retina. 2010 Feb;30(2):235-45 - PubMed
    1. Doc Ophthalmol. 2008 Mar;116(2):79-89 - PubMed

Publication types

LinkOut - more resources